TDOC - Teladoc Health, Inc. Stock Analysis | Stock Taper
Logo
Teladoc Health, Inc.

TDOC

Teladoc Health, Inc. NYSE
$5.26 -1.68% (-0.09)

Market Cap $933.51 M
52w High $9.94
52w Low $4.40
P/E -4.17
Volume 11.97M
Outstanding Shares 177.47M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $642.27M $481.22M $-25.14M -3.91% $-0.14 $51.11M
Q3-2025 $626.44M $491.22M $-49.51M -7.9% $-0.28 $-35.18M
Q2-2025 $631.9M $495.75M $-32.66M -5.17% $-0.19 $2.67M
Q1-2025 $629.37M $553.15M $-93.01M -14.78% $-0.53 $-8.96M
Q4-2024 $640.49M $499.78M $-48.41M -7.56% $-0.28 $11.78M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $781.08M $2.86B $1.47B $1.39B
Q3-2025 $726.25M $2.88B $1.49B $1.39B
Q2-2025 $679.62M $2.89B $1.47B $1.42B
Q1-2025 $1.19B $3.44B $2.02B $1.43B
Q4-2024 $1.3B $3.52B $2.03B $1.49B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2025 $-25.14M $87.74M $-34.32M $1.1M $54.84M $85.12M
Q3-2025 $-49.51M $99.26M $-48.72M $-3.59M $46.63M $67.95M
Q2-2025 $-32.66M $91.43M $-59.7M $-549.93M $-513.71M $90.16M
Q1-2025 $-93.01M $15.92M $-123.27M $769K $-105M $-15.67M
Q4-2024 $-48.41M $85.9M $-29.64M $2.06M $54.46M $56.26M

Revenue by Products

Product Q3-2024Q1-2025Q2-2025Q3-2025
Other
Other
$90.00M $100.00M $110.00M $110.00M

Revenue by Geography

Region Q1-2025Q2-2025Q3-2025Q4-2025
NonUS
NonUS
$100.00M $110.00M $120.00M $120.00M
UNITED STATES
UNITED STATES
$520.00M $520.00M $510.00M $520.00M

Q4 2025 Earnings Call Summary

Read Call Summary

5-Year Trend Analysis

A comprehensive look at Teladoc Health, Inc.'s financial evolution and strategic trajectory over the past five years.

+ Strengths

Teladoc combines a sizable revenue base, strong gross margins, and solid free cash flow with a leading position in virtual care. Its balance sheet shows good liquidity and manageable leverage, giving it time and flexibility to refine its business model. The integrated Prism platform, large provider network, and rich data assets provide a strong foundation for differentiated offerings such as chronic care management, primary care, and mental health. Continued investment in AI and platform innovation positions the company to benefit from the long‑term shift toward digital and remote healthcare.

! Risks

Key risks center on persistent unprofitability, high operating expenses, and significant accumulated losses. A large share of assets are intangible and tied to past acquisitions, creating potential for future impairments if segments underperform. Competitive pressures from big tech, health systems, and specialized digital health startups could squeeze pricing and limit growth in certain lines of business. Regulatory and reimbursement uncertainty in telehealth adds further complexity. Internally, the performance and strategic direction of segments like BetterHelp remain important swing factors for both perception and financial results.

Outlook

The overall outlook is mixed but still opportunity‑rich. On one hand, Teladoc operates in a growing market with structural tailwinds as healthcare delivery becomes more digital, and it has the scale, technology, and cash generation to remain a central player. On the other hand, it must prove that its integrated, whole‑person care model can support sustainable profitability and justify past acquisition spending. Future progress will likely be judged on the company’s ability to improve operating leverage, maintain its innovation edge, and demonstrate clear value to employers, health plans, and patients in a crowded and evolving competitive landscape.